Steroid-based therapy for Cardiomyopathy: ProstaglandinE2 (PGE2) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 15/July/2017, 11.21 pm

Hypothermia therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: Hypothermia therapy increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state via up-regulation of its target gene Lin28, 15/July/2017, 12.31 am
July 14, 2017
Natural product-derived regenerative therapy for reversing diabetes:Fisetin, isolated from Strawberry, increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 16/July/2017, 12.25 pm
July 15, 2017
Show all

Introduction: What they say

A recent study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that Trbp regulates heart function through microRNA-mediated Sox6 repression.” This study was published, in the 2 June  2015 issue of the journal “Nature Genetics” (the number 1 research journal in Genetics with an impact factor of 29.648), by ProfDa-Zhi Wang & Jian Ding, and others


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Steroid-based therapy for Cardiomyopathy:  ProstaglandinE2 (PGE2) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) Dilated cardiomyopathy is the leading cause of Heart failure; (3) the raise  of death rate, due to cardiovascular disease, has increased from 12.3 million in 1990 to 17.3 million in 2013; (4) 13% of cardiovascular disease occur due to  uncontrolled high blood pressure; (5) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (6) 85% of people over  80 years are susceptible to cardiovascular diseases; (7) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (8) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; and (9) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find:  (i) a cure to diseases, as mentioned above, leading to cardiovascular disease; (ii) a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (iii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


What is known?

A number of studies suggests that Cardiomyopathy is the result of altered gene expression of contractile proteins. Trbp, an RNA binding protein, has been shown to be required for normal functioning of heart contractions.

Prof Da-Zhi Wang‘s research team has shown earlier that inactivation of Trbp in mice leads to progressive cardiomyopathy and heart failure. 


From research findings to Therapeutic opportunity: 

I have published earlier that Prostaglandin E2 (PGE2) may protect against Cardiomyopathy (https://genomediscovery.org/2015/06/33833/). However, the study reported here has identified a new mechanism of action for Prostaglandin E2 (PGE2). PGE2, by increasing the expression of its target gene, it may: (1) decrease the expression of Sox6; (2) increase the expression of cardiac slow-twitch myofiber proteins; (3) decrease the expression of skeletal fast-twitch myofiber proteins (4) restore the balance between slow- and fast-twitch myofiber proteins; (5) increase the proliferation of cardiomyocyte stem cells; (6) increase the number of beating cardiomyocytes; and (7) alleviate cardiomyopathy (fig. 1).

Figure 1. ProstaglandinE2 (PGE2) as a cardioprotective agent. ProstaglandinE2 (PGE2), by increasing the expression of its target gene, it may decrease the expression of Sox6. Thereby, it may increase cardiomyocyte proliferation, augment the number of beating cardiomyocytes, and attenuate cardiomyopathy

Thus, pharmacological formulations encompassing ProstaglandinE2 (PGE2) or its analogues, either alone or in combination with other drugs” may be used to inhibit progressive cardiomyopathy and lethal heart failure.

Given the non-toxic nature of ProstaglandinE2 (PGE2), it may be a preferable agent to treat cardiomyopathy and heart failure.

[easy_payment currency=”USD”]


Details of the research findings:

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How ProstaglandinE2 (PGE2) inhibits the expression of Sox6.

#Research cooperation

Amount: $300#

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org

To citeBoominathan, L., Steroid-based therapy for Cardiomyopathy:  ProstaglandinE2 (PGE2) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 15/July/2017,  11.21 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.